earli
phase
diseas
rapid
expans
matur
natur
killer
cell
earli
transplant
result
lower
probabl
relaps
suggest
graft
vs
leukemia
effect
independ
graftvshost
reaction
prospect
analyz
outcom
haploident
hematopoiet
stem
cell
transplant
use
tcell
deplet
graft
sixtythre
transplant
perform
patient
twentyeight
patient
diagnos
acut
lymphoblast
leukemia
patient
diagnos
acut
myelogen
leukemia
eight
hematolog
malign
diagnos
twentythre
first
complet
remiss
cr
second
cr
beyond
second
cr
four
patient
develop
graft
failur
median
time
neutrophil
platelet
recoveri
rang
day
rang
respect
probabl
nonrelaps
mortal
nrm
day
transplant
median
followup
month
probabl
relaps
diseasefre
surviv
immun
reconstitut
lead
nk
cell
high
dim
bright
nk
cell
ratio
earli
transplant
associ
better
diseasefre
surviv
df
vs
p
due
lower
relaps
incid
vs
p
tcell
reconstitut
delay
associ
sever
infect
transplant
viral
reactivationdiseas
presenc
venooclus
diseas
liver
noncaucasian
popul
signific
impact
nrm
tcell
celldeplet
haploident
transplant
associ
good
outcom
especi
patient
nowaday
allogen
hematopoiet
stem
cell
transplant
consid
cur
option
pediatr
patient
highrisk
leukemia
diagnosi
relaps
howev
import
proport
patient
lack
suitabl
human
leucocyt
antigen
hla
match
donor
delay
donor
avail
may
unaccept
patient
need
allogen
transplant
time
manner
use
haploident
rel
donor
consid
suitabl
approach
donor
tcell
graft
facilit
tcell
reconstitut
also
respons
graftvshost
diseas
gvhd
current
sever
haploident
transplant
platform
use
exvivo
tcell
deplet
tcd
without
use
posttranspl
gvhd
pharmacolog
prophylaxi
gain
clinic
relev
natur
killer
nk
cell
detect
first
week
follow
tcd
haploident
transplant
pattern
express
killer
cell
immunoglobulinlik
receptor
kir
similar
origin
found
donor
howev
nk
cell
phenotyp
alter
cytotox
lower
compar
donor
pediatr
patient
receiv
deplet
haploident
transplant
mention
tcd
haploident
transplant
platform
associ
encourag
result
especi
patient
earli
phase
diseas
kirb
haplotyp
donor
confer
rapid
nk
cell
expans
earli
transplant
result
lower
probabl
relaps
use
graft
younger
donor
result
improv
immun
reconstitut
lymphocyt
subset
howev
viral
reactiv
affect
signific
proport
patient
new
approach
improv
delay
immun
reconstitut
recent
develop
base
select
deplet
lymphocyt
b
cell
previou
tcell
deplet
strategi
result
loss
lymphocyt
cell
subset
may
play
posit
role
recipi
cell
display
tcell
receptor
tcr
respons
gvhd
howev
cell
receptor
chain
alloreact
capac
may
contribut
import
antiinfecti
activ
possibl
antileukemia
effect
recent
public
use
mention
haploident
transplant
platform
mainli
focus
earli
immun
reconstitut
especi
cell
subset
howev
studi
report
detail
analysi
prognost
factor
outcom
type
transplant
consid
earli
immun
reconstitut
impact
transplant
outcom
aim
observ
prospect
studi
analyz
outcom
risk
factor
surviv
pediatr
patient
receiv
haploident
rel
donor
transplant
use
deplet
graft
patient
enrol
studi
novemb
novemb
consecut
patient
younger
year
old
diagnos
highrisk
hematolog
malign
need
allogen
transplant
good
clinic
condit
lack
either
match
relat
donor
match
unrel
donor
includ
indic
allogen
hematopoiet
transplant
children
acut
lymphoblast
leukemia
includ
poor
cytogenet
induct
failur
defin
remiss
month
follow
induct
treatment
persist
minim
residu
diseas
test
pcr
transplant
cutoff
point
complet
remiss
cr
beyond
acut
myeloid
leukemia
aml
patient
transplant
criteria
includ
intermedi
poor
risk
characterist
diagnosi
also
cr
beyond
primari
refractori
aml
defin
failur
achiev
respons
one
two
cycl
induct
refractori
defin
failur
achiev
cytolog
remiss
respons
induct
chemotherapi
secondlin
rescu
chemotherapi
exclus
criterion
poor
clinic
condit
defin
lanski
score
lower
patient
parent
andor
legal
guardian
gave
written
inform
consent
accord
helsinki
declar
sixtythre
transplant
perform
patient
twentyeight
patient
aml
five
advanc
myelodysplast
syndrom
md
two
hodgkin
diseas
one
nonhodgkin
lymphoma
twentythre
first
cr
second
cr
second
cr
activ
diseas
time
transplant
twentytwo
patient
mrd
posit
time
transplant
haploident
first
transplant
case
case
one
two
previou
stem
cell
transplant
subsequ
chemotherapi
cours
haploident
transplant
perform
patient
transplant
characterist
shown
tabl
fifteen
human
kir
gene
two
pseudogen
analyz
pcr
kir
type
kit
miltenyi
biotec
bergisch
gladbach
germani
kir
haplotyp
defin
absenc
presenc
kiractiv
receptor
kir
b
haplotyp
determin
presenc
activ
gene
except
kir
ligand
hlac
allotyp
hlab
allotyp
determin
use
highresolut
pcrsequencebas
type
also
determin
kir
bcontent
score
donor
accord
system
propos
cooley
et
al
www
ebiacukipdkirdonorbcontenthtml
criteria
donor
select
previous
report
briefli
donor
chosen
base
kir
b
haplotyp
higher
bcontent
score
younger
age
nk
alloreact
kirligand
model
donor
parent
mother
father
sibl
donor
characterist
also
shown
tabl
donor
mobil
previous
describ
briefli
mobil
start
day
condit
regimen
gcsf
dose
subcutan
base
volum
dose
may
split
two
inject
site
progenitor
cell
collect
perform
leukapheresi
product
obtain
largevolum
leukapheresi
procedur
accord
establish
protocol
center
use
continu
flow
blood
cell
separ
spectra
optia
mnc
terumo
bct
lakewood
co
usa
cobe
spectra
tm
caridian
bct
europ
garch
germani
fifth
day
mobil
day
infus
apheresi
carri
via
bilater
peripher
vein
whenev
possibl
otherwis
central
venou
cathet
leukapheresi
blood
volum
process
acid
citrat
dextros
acda
use
anticoagul
ratio
leukapheresi
product
also
analyz
express
antigen
previous
report
concurr
plasma
ml
collect
product
store
overnight
receipt
process
facil
uniqu
identif
label
system
use
track
leukapheresi
product
collect
infus
accord
factjaci
guidelin
target
dose
cellskg
select
contain
tcr
cellskg
desir
two
collect
minimum
requir
dose
cell
dose
per
kg
reach
collect
perform
tcell
deplet
perform
use
clinimac
plu
devic
fulli
autom
prodigi
devic
manipul
laminarflow
cabinet
locat
clean
room
certifi
steril
manipul
clinic
grade
reagent
dispos
kit
instrument
miltenyi
biotec
bergisch
gladbach
germani
deplet
procedur
cell
composit
apheresi
product
analyz
flow
cytometri
cell
count
cell
subpopul
cell
viabil
adjust
dose
total
nucleat
cell
tnc
cell
maxim
capac
tnc
tcell
case
clinimac
system
clinimac
system
miltenyi
biotec
germani
tnc
tcell
case
prodigi
devic
prodigi
system
miltenyi
biotec
germani
accord
manufactur
instruct
use
clinimac
prodigi
devic
togeth
clinimac
prodigi
clinimac
tcr
biotin
reagent
clinimac
antibiotin
reagent
clinimac
reagent
clinimac
pbsedta
obtain
miltenyi
biotec
gmbh
bergischgladbach
germani
select
process
lp
tct
deplet
normal
scale
process
use
follow
reagent
clinimac
tcr
biotin
reagent
clinimac
antibiotin
reagent
clinimac
reagent
vial
clinimac
pbsedta
clinimac
tube
set
instal
liquid
connect
prompt
devic
cell
pass
magnet
field
separ
thu
lymphocyt
removedeliminatedretain
unlabel
cell
recov
subsequ
transplant
patient
end
procedur
qualiti
control
flow
cytometri
carri
final
product
cell
count
viabil
studi
aerob
anaerob
cultur
immunomagnet
deplet
deplet
procedur
perform
clinimac
plu
system
deplet
perform
clinimac
prodigi
devic
accord
avail
devic
none
apheresi
product
exceed
maxim
capacitylimit
tnc
cell
establish
manufactur
begin
manipul
procedur
median
recoveri
clinimac
plu
clinimac
prodigi
without
reach
statist
signific
signific
differ
term
cell
deplet
efficaci
assess
logarithm
descent
vs
p
median
infus
dose
cellskg
cell
group
howev
higher
number
infus
tcellskg
recipi
bodi
weight
use
clinimac
prodigi
kg
vs
clinimac
plu
kg
p
data
cell
composit
final
apheresi
product
deplet
procedur
use
system
provid
supplement
tabl
cellular
product
freshli
infus
day
condit
regimen
consist
fludarabin
mgm
day
day
busulfan
mgkgday
accord
patient
bodi
weight
day
thiotepa
mgkgday
day
methylprednisolon
administ
day
mgkg
serotherapi
given
part
transplant
condit
patient
requir
second
haploident
transplant
due
primari
graft
failur
condit
regimen
use
consist
fludarabin
mgm
day
day
thymoglobulin
mgkgday
day
melphalan
mgm
day
cyclosporin
use
pharmacolog
gvhd
prophylaxi
day
engraft
tailor
soon
possibl
transplant
whenev
acut
gvhd
present
myeloid
recoveri
defin
first
consecut
day
absolut
neutrophil
count
l
platelet
recoveri
time
consid
first
consecut
day
platelet
count
l
achiev
transfus
requir
donor
chimer
evalu
short
tandem
repeat
pcr
method
time
engraft
monthli
follow
transplant
clinic
condit
requir
donor
chimer
determin
whole
blood
cell
subset
chimer
analysi
subpopul
progenitor
cell
bone
marrow
lymphocyt
peripher
blood
purifi
immunomagnet
method
bead
miltenyi
biotec
phenotyp
nk
cell
lymphocyt
lymphocyt
subset
b
lymphocyt
nkt
lymphocyt
dendrit
cell
dc
perform
fresh
sampl
whole
blood
multiparametr
flow
cytometri
previous
describ
follow
fluorochromelabel
monoclon
ab
human
ag
obtain
becton
dickinson
san
jose
ca
usa
lineagefitc
fluorochromelabel
monoclon
ab
obtain
beckman
coulter
fullerton
ca
usa
fluorochromelabel
monoclon
ab
obtain
miltenyi
biotec
major
studi
endpoint
diseasefre
surviv
df
cumul
incid
relaps
nonrelaps
mortal
nrm
df
defin
time
transplant
relapseprogress
death
caus
whichev
occur
first
acut
gvhd
agvhd
grade
accord
standard
criteria
wherea
chronic
gvhd
cgvhd
defin
mild
moder
sever
accord
nih
criteria
chronic
gvhd
relaps
defin
morpholog
clinic
evid
recurr
peripher
blood
bone
marrow
extramedullari
site
nrm
defin
caus
death
diseas
probabl
df
calcul
time
neutrophil
time
platelet
l
time
platelet
l
time
platelet
l
support
care
day
time
transplant
mean
kaplanmei
product
limit
method
cumul
incid
use
estim
relaps
nrm
probabl
death
remiss
treat
compet
event
calcul
cumul
relaps
incid
relaps
consid
compet
event
calcul
cumul
incid
nrm
gray
test
use
assess
differ
relaps
incid
nrm
multivari
analysi
surviv
evalu
use
proport
hazard
regress
model
hazard
ratio
hr
calcul
confid
interv
ci
p
consid
statist
signific
follow
variabl
includ
analysi
covari
patient
donor
age
diagnosi
diseas
statu
time
transplant
cell
graft
composit
kir
ligand
mismatch
statu
donor
kir
haplotyp
kir
b
score
kinet
immun
reconstitut
end
point
calcul
time
last
contact
loss
followup
death
statist
analys
data
perform
use
statist
packag
spss
macintosh
softwar
version
ibm
corpor
armonk
ny
usa
r
softwar
packag
macintosh
version
r
four
patient
develop
primari
graft
failur
rescu
use
second
allogen
transplant
median
time
neutrophil
recoveri
engraft
patient
day
rang
median
time
platelet
engraft
day
rang
data
engraft
kinet
provid
tabl
patient
achiev
full
donor
chimer
time
engraft
patient
requir
platelet
transfus
median
time
day
rang
median
durat
red
blood
cell
transfus
day
rang
data
support
care
also
provid
tabl
toxic
profil
shown
tabl
seventeen
patient
develop
engraft
syndrom
es
seven
patient
develop
venoocclus
diseasesinusoid
obstruct
syndrom
vodso
liver
thrombot
microangiopathi
complic
significantli
associ
ethnic
incid
vodso
caucasian
wherea
noncaucasian
rose
rang
p
median
hospit
time
hematopoiet
cell
infus
day
rang
immun
reconstitut
character
patient
engraft
rapid
increas
nk
cell
nk
cell
count
peak
day
median
rang
median
number
dim
nk
cell
day
wherea
median
number
bright
nk
cell
day
median
dim
bright
nk
cell
ratio
day
rang
day
nk
cell
popul
slowli
decreas
median
day
ultim
nk
cell
count
remain
steadi
tcell
recoveri
delay
median
number
rang
day
rang
day
rang
day
rang
day
relationship
infus
cell
dose
tcell
recoveri
r
p
reconstitut
b
lymphocyt
also
delay
start
median
rang
day
progress
increas
reach
rang
day
rang
day
observ
gradual
increas
dc
popul
time
median
rang
day
rang
day
detail
data
lymphoid
subpopul
recoveri
kinet
shown
supplement
tabl
supplement
figur
thirtyf
patient
develop
agvhd
grade
n
grade
n
grade
n
grade
n
probabl
agvhd
grade
higher
median
time
agvhd
day
rang
day
fourteen
patient
develop
cgvhd
mild
six
case
moder
six
case
sever
six
case
probabl
median
time
cgvhd
day
rang
day
found
variabl
associ
develop
neither
acut
chronic
gvhd
median
followup
month
rang
cumul
incid
nrm
seven
patient
die
day
later
time
median
time
death
day
rang
univari
analysi
reveal
nrm
influenc
ethnic
white
caucasian
vs
noncaucasian
p
presenc
so
ye
vs
p
develop
sever
agvhd
ye
vs
p
dim
bright
nk
cell
ratio
day
low
vs
high
howev
multivari
analysi
show
presenc
so
variabl
associ
nrm
hr
ci
p
primari
caus
death
shown
tabl
infecti
episod
diagnos
use
microbiolog
andor
clinic
criteria
median
followup
survivor
month
rang
month
patient
relaps
median
time
relaps
day
rang
day
cumul
incid
follow
variabl
influenc
probabl
relaps
univari
analysi
diseas
phase
transplant
earli
phase
vs
advanc
phase
p
high
dim
bright
nk
cell
ratio
day
vs
p
type
acut
leukemia
myeloid
vs
lymphoid
p
multivari
analysi
mva
show
relaps
influenc
type
malign
dim
bright
nk
cell
ratio
day
transplant
tabl
probabl
df
whole
group
tabl
df
curv
accord
mva
shown
figur
allogen
hematopoiet
stem
cell
transplant
haploident
donor
suitabl
transplant
option
patient
lack
hlaident
donor
nowaday
sever
haploident
transplant
platform
gain
clinic
relev
use
exvivo
tcell
deplet
tcd
tcd
haploident
set
differ
techniqu
graft
manipul
develop
last
year
avoid
minim
undesir
gvhd
techniqu
evolv
initi
almost
total
b
cell
deplet
mean
isol
deplet
recent
graft
manipul
techniqu
deplet
result
partial
tcd
maintain
nk
cell
attempt
improv
immun
reconstitut
follow
transplant
approach
circumv
delay
immun
recoveri
repres
sophist
method
graft
manipul
recent
develop
implement
base
select
deplet
tcell
bcell
strategi
allow
infus
donor
hematopoiet
stem
cell
also
commit
hematopoiet
progenitor
matur
nk
cell
tcell
recent
haploident
transplant
tcellbcel
deplet
shown
effect
singlecent
studi
studi
myeloabl
total
bodi
irradi
tbi
condit
regimen
combin
serotherapi
use
report
studi
use
chemotherapybas
condit
regimen
even
serotherapi
part
condit
children
acut
leukemia
receiv
haploident
transplant
use
tcellbcel
deplet
rel
lower
risk
acut
chronic
gvhd
even
transplant
unrel
donor
howev
major
challeng
relaps
diseas
delay
immun
reconstitut
lead
infecti
morbid
mortal
immun
reconstitut
studi
risk
factor
transplant
outcom
analysi
use
tcd
haploident
platform
need
herein
report
risk
factor
analysi
detail
analysi
immun
reconstitut
impact
transplant
outcom
prospect
studi
use
haploident
transplant
tcellbcel
deplet
chemotherapybas
condit
regimen
serotherapi
main
find
present
studi
comment
first
engraft
kinet
fast
probabl
due
larg
number
infus
progenitor
tabl
recent
publish
author
note
graft
deplet
contain
high
number
previou
graft
manipul
procedur
use
condit
regimen
similar
publish
studi
use
tbibas
condit
without
serotherapi
part
preparatori
regimen
nonradiationbas
prepar
regimen
use
pediatr
patient
highrisk
acut
leukemia
busulfanbas
myeloabl
condit
regimen
report
safe
effect
hematopoiet
transplant
import
observ
studi
fact
condit
regimen
welltoler
tabl
low
incid
sever
complic
similar
recent
publish
adult
children
howev
observ
high
incid
sever
vodso
noncaucasian
popul
previous
observ
report
complic
associ
high
mortal
mention
popul
noncaucasian
mainli
white
hispan
patient
increasingli
includ
transplant
program
institut
possibl
interethn
variabl
genet
polymorph
frequenc
metabol
enzym
probabl
influenc
toxic
incid
vodso
base
find
ethnic
consid
potenti
risk
factor
prospect
vodso
studi
incid
es
remark
tabl
es
inflammatori
condit
occur
hsct
character
noninfecti
fever
skin
rash
previous
report
complic
pediatr
haploident
transplant
set
use
tcd
platform
es
consid
herald
gvhd
complic
might
relat
use
serotherapi
part
preparatori
regimen
howev
complic
impact
clinic
outcom
seri
second
immun
reconstitut
preced
rapid
sustain
appear
nkcell
supplement
tabl
immun
reconstitut
allogen
transplant
depend
multipl
factor
stem
cell
sourc
dose
graft
manipul
procedur
donor
age
condit
regimen
posttranspl
immunosuppress
use
other
previous
report
immun
reconstitut
children
receiv
tcd
haploident
transplant
character
earli
fast
nkcell
recoveri
constitut
major
lymphocyt
subpopul
earli
phase
follow
transplant
nkcell
graft
fast
nkcell
recoveri
consid
import
allogen
transplant
especi
haploident
transplant
condit
blood
high
level
provid
favor
environ
matur
donor
nkcell
infus
also
nkcell
matur
engraft
hsc
nkcell
reconstitut
function
follow
haploident
transplant
clearli
influenc
gvhd
prophylaxi
especi
postcyclophosphamid
elimin
matur
donor
nk
cell
includ
alloreact
nk
cell
recent
publish
previous
observ
higher
nkcell
number
earli
posttranspl
lower
incid
relaps
result
better
outcom
use
deplet
graft
analyz
potenti
impact
dim
bright
nk
cell
subpopul
relaps
incid
observ
higher
dim
bright
nk
cell
ratio
lower
relaps
incid
result
better
df
relev
role
nk
cell
infus
graft
tcd
allogen
transplant
set
previous
publish
number
nk
cell
graft
power
determin
relaps
risk
analysi
nk
cell
subset
clearli
show
gvl
effect
mediat
dim
popul
highlevel
express
activatori
receptor
dnam
dim
popul
cell
also
strongli
protect
howev
similar
analysi
publish
tcd
haploident
set
recent
studi
pediatr
patient
receiv
tcell
deplet
haploident
transplant
show
overshoot
nk
cell
recoveri
day
compar
donor
level
despit
rapid
expans
bright
nk
cell
subset
dim
nk
cell
predomin
studi
time
period
howev
report
correl
dim
bright
recoveri
relaps
incid
previou
data
indic
number
total
nk
cell
earli
transplant
strong
determin
gvl
effect
specif
dim
bright
nk
cell
ratio
predict
diseas
relaps
relev
impact
df
usual
dim
nk
cell
constitut
around
peripher
blood
nk
cell
healthi
donor
nk
cell
power
activ
viru
transform
cell
cancer
cell
special
aml
cell
activ
cancer
cell
mainli
support
dim
cytotox
activ
bright
popul
differ
cytokin
profil
result
lower
cytotox
cancer
cell
higher
dim
bright
nk
cell
ratio
might
result
cytotox
exert
dim
subset
lower
risk
relaps
unfortun
data
cytotox
seri
support
explan
altern
nk
cell
could
act
boost
tcell
activ
might
increas
tcell
base
gvl
effect
howev
data
clearli
show
tcell
recoveri
delay
longer
period
time
follow
transplant
especi
tcell
cytokin
necessari
nkcell
homeostasi
develop
also
tcell
earli
phase
follow
transplant
high
level
recipi
provid
favor
environ
nk
cell
tcell
prolifer
matur
function
earli
reconstitut
nk
tcell
compar
healthi
donor
observ
allogen
match
sibl
match
unrel
donor
fact
observ
associ
earli
immun
reconstitut
risk
sever
infect
howev
despit
rapid
innat
immun
reconstitut
relev
incid
viral
reactiv
previous
report
earli
posttranspl
phase
tcell
lead
respons
infect
tcell
recoveri
delay
compar
nk
cell
especi
tcell
howev
observ
even
earli
transplant
tcell
predomin
tcell
popul
despit
low
number
tcell
infus
slow
tcell
reconstitut
clearli
relat
risk
opportunist
larg
viral
infect
furthermor
infect
lead
caus
nrm
second
lead
caus
death
relaps
diseas
tabl
third
consid
result
df
whole
group
accept
take
account
stage
diseas
studi
popul
expect
particularli
good
patient
transplant
first
cr
import
result
relev
proport
patient
underw
transplant
advanc
phase
diseas
even
activ
diseas
rescu
haploident
transplant
still
continu
cr
incid
cgvhd
lower
observ
use
deplet
although
patient
develop
mild
moder
cgvhd
near
requir
protract
treatment
howev
cgvhd
associ
better
df
primarili
due
better
control
diseas
relaps
although
median
followup
long
enough
consid
result
matur
believ
encourag
support
idea
use
haploident
donor
earli
possibl
whenev
patient
need
hsct
sever
conclus
drawn
first
haploident
transplant
use
deplet
yield
encourag
result
especi
patient
undergo
transplant
earli
phase
diseas
complet
remiss
second
condit
regimen
use
welltoler
third
ethnic
may
predispos
develop
sever
liver
toxic
impli
increas
risk
nrm
fourth
viral
infectiondiseas
still
continu
unresolv
problem
clearli
associ
delay
tcell
recoveri
impact
caus
death
transplant
need
rebuild
tcell
reconstitut
exit
last
least
rapid
sustain
matur
nk
cell
reconstitut
result
better
diseas
control
better
transplant
outcom
would
support
use
fresh
stimul
nk
cell
infus
earli
transplant
enhanc
gvl
risk
gvhd
dataset
gener
studi
avail
request
correspond
author
ethic
review
approv
requir
studi
human
particip
accord
local
legisl
institut
requir
written
inform
consent
particip
studi
provid
particip
legal
guardiannext
kin
